ADMA Biologics Inc (NASDAQ:ADMA – Get Free Report) has been given an average recommendation of “Moderate Buy” by the six brokerages that are currently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $18.67.
Several equities research analysts recently issued reports on the company. Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a report on Monday, September 14th. Finally, Mizuho dropped their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th.
View Our Latest Report on ADMA Biologics
Hedge Funds Weigh In On ADMA Biologics
ADMA Biologics Stock Up 4.2%
NASDAQ ADMA opened at $11.75 on Friday. The stock has a market cap of $2.63 billion, a PE ratio of 16.79 and a beta of 0.70. ADMA Biologics has a fifty-two week low of $7.21 and a fifty-two week high of $20.46. The business has a 50 day moving average price of $9.97 and a two-hundred day moving average price of $11.07. The company has a quick ratio of 3.81, a current ratio of 6.97 and a debt-to-equity ratio of 0.49.
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.16. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%. The business had revenue of $124.39 million for the quarter, compared to analyst estimates of $125.34 million. During the same period in the previous year, the company earned $0.14 earnings per share. The company’s revenue for the quarter was up 2.0% compared to the same quarter last year. As a group, sell-side analysts predict that ADMA Biologics will post 0.78 EPS for the current fiscal year.
ADMA Biologics Company Profile
ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.
ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.
Recommended Stories
- Five stocks we like better than ADMA Biologics
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
